Table 1.
The demographic and clinical characteristics of patients in cycle 1.
| Variables | All patients (n = 202) | With < Grade 3 neutropenia (n = 178) | With ≥Grade 3 neutropenia (n = 24) | p-value |
|---|---|---|---|---|
| PATIENT FACTORS | ||||
| Age, mean (SD), y | 52.6 ± 10.8 | 52.3 ± 11.1 | 54.9 ± 7.9 | 0.255 |
| Gender, Male, n (%) | 126 (62.4%) | 111 (62.4%) | 15 (62.5%) | 0.989 |
| Body mass index mean (SD), kg/m2 | 22.5 ± 3.8 | 22.8 ± 2.7 | 22.3 ± 4.1 | 0.895 |
| Education | ||||
| Illiterate/primary or high school | 89.6% (181/202) | 89.9% (160/178) | 87.5% (21/24) | 0.719 |
| Undergraduate or higher | 10.4% (21/202) | 10.1% (18/178) | 12.5% (3/24) | |
| Socioeconomic status | ||||
| Low to moderate income | 86.1% (174/202) | 84.8% (151/178) | 95.8% (20/24) | 0.143 |
| High income | 13.9% (28/202) | 15.2% (27/178) | 4.2% (1/24) | |
| Smoking | ||||
| Yes | 23.8% (48/202) | 24.7% (44/178) | 16.7% (4/24) | 0.384 |
| No | 76.2% (154/202) | 75.3% (134/178) | 83.3% (20/24) | |
| Alcohol | ||||
| Yes | 12.4% (25/202) | 11.8% (21/178) | 16.7% (4/24) | 0.497 |
| No | 87.6% (177/202) | 88.2% (157/178) | 83.3% (20/24) | |
| LABORATORY FACTORS | ||||
| Albumin (g/L), mean (SD) | 41.0 ± 3.85 | 41.4 ± 3.62 | 38.1 ± 4.15 | 0.001 |
| Prealbumin (mg/L), mean (SD) | 221.1 ± 51.0 | 224.7 ± 52.9 | 194.3 ± 17.1 | 0.006 |
| Absolute neutrophil count (*109/L), mean (SD) | 3.51 ± 1.57 | 3.56 ± 1.60 | 3.15 ± 1.36 | 0.231 |
| Absolute lymphocyte count (*109/L), mean (SD) | 1.66 ± 0.6 | 1.70 ± 0.7 | 1.32 ± 0.4 | 0.007 |
| Platelet count (*109/L), mean (SD) | 255.0 ± 89.0 | 258.8 ± 91.3 | 227.1 ± 63.5 | 0.101 |
| Hemoglobin (g/L), mean (SD) | 120.6 ± 25.5 | 122.2 ± 23.7 | 108.8 ± 34.4 | 0.015 |
| eGFR (mL/min), mean (SD) | 94.3 ± 16.4 | 94.3 ± 16.7 | 94.4 ± 14.4 | 0.990 |
| Serum CEA | ||||
| Normal | 69.3% (140/202) | 69.7% (124/178) | 66.7% (16/24) | 0.765 |
| Elevated | 30.7% (62/202) | 30.7% (54/178) | 33.3% (8/24) | |
| Serum prealbumin | ||||
| ≥200 mg/L | 64.9% (131/202) | 69.1% (123/178) | 33.3% (8/24) | 0.001 |
| <200 mg/L | 35.1% (71/202) | 30.9% (55/178) | 66.7% (16/24) | |
| PNI | ||||
| ≥51.2 | 39.1% (79/202) | 43.3% (77/178) | 8.3% (2/24) | 0.001 |
| <51.2 | 60.9% (123/202) | 56.7% (101/178) | 91.7% (22/24) | |
| DISEASE FACTORS | ||||
| TNM stage | ||||
| II | 60.9% (123/202) | 61.8% (110/178) | 54.2% (13/24) | 0.472 |
| III | 39.1% (79/202) | 38.2% (68/178) | 45.8% (11/24) | |
| Lymph node metastasis | ||||
| No | 38.6% (78/202) | 41.0% (73/178) | 16.7% (4/24) | 0.021 |
| Yes | 61.4% (124/202) | 59.0% (105/178) | 83.3% (20/24) | |
| Tumor size (cm), mean (SD) | 4.1 ± 1.9 | 3.8 ± 1.7 | 6.0 ± 2.6 | 0.001 |
| Differentiation | ||||
| High/moderate | 47.5% (96/202) | 51.1% (91/178) | 20.8% (5/24) | 0.005 |
| Poor | 52.5% (106/202) | 48.9% (87/178) | 79.2% (19/24) | |
| PERIOPERATIVE FACTORS | ||||
| Operation | ||||
| Laparoscopic | 96.5% (195/202) | 96.6% (172/178) | 95.8% (23/24) | 0.611 |
| Open | 3.5% (7/202) | 3.4% (6/178) | 4.2% (1/24) | |
| Complications | ||||
| No | 86.6% (175/202) | 87.1% (155/178) | 83.3% (20/24) | 0.613 |
| Grade 1 & 2 | 13.4% (27/202) | 12.9% (23/202) | 16.7% (4/24) | |
| Time between AC and operation, median, days | 29 ± 10 | 30 ± 11 | 26 ± 2 | 0.135 |
| Neutropenia in cycle 1 | ||||
| No | 48.0% (97/202) | N/A | N/A | N/A |
| Grade 1 | 27.2% (55/202) | |||
| Grade 2 | 12.9% (26/202) | |||
| Grade 3 | 10.9% (22/202) | |||
| Grade 4 | 1.0% (2/202) | |||
For p-value: Boldface type indicates significant difference.
SD, standard deviation; eGFR, estimated glomerular filtration rate; CEA, carcinoembryonic antigen; TNM, tumor-node-metastasis; AC, adjuvant chemotherapy; PNI, prognostic nutritional index; N/A, not available.